Literature DB >> 28729525

Expression of Fibrogenic Markers in Tumor and Tumor-Surrounding Tissue at Time of Transplantation Correlates with Recurrence of Hepatocellular Carcinoma in Patients Undergoing Liver Transplantation.

Peri Kocabayoglu1, Katja Piras-Straub2, Guido Gerken2, Andreas Paul1, Kerstin Herzer1,2.   

Abstract

BACKGROUND Liver transplantation (LT) remains the only curative treatment option for patients with defined stages of hepatocellular carcinoma (HCC). Up to 25% of patients show a tumor recurrence following transplantation. The correlation of fibrogenic markers prior to LT with HCC recurrence has not been characterized. We explored the expression of fibrogenic markers in tumor tissue and tumor-surrounding liver tissue of patients undergoing LT and correlated these findings with tumor recurrence. MATERIAL AND METHODS Fibrogenic marker expression in explanted livers was assessed using tumor and tumor-surrounding liver tissue from patients who recently underwent liver transplantation at our center with a follow-up period of at least 3 years. Tissue was analyzed for the expression of fibrogenic proteins and genes, as well as collagen deposition into the extracellular matrix. Results were correlated with HCC recurrence. RESULTS Patients with recurrent HCC following LT exhibited increased levels of fibrogenic markers on both protein and RNA level within the non-tumorous liver tissue in comparison to the tumor tissue itself. Patients who did not develop tumor recurrence up to 4 years after LT showed a reversed expression pattern of fibrogenic markers with decreased levels of β-PDGFR, Collagen 1, and α-SMA in their non-tumorous liver tissue versus the tumor tissue at time of LT as assessed in protein and mRNA expression analysis. These findings correlated with analysis of collagen deposition in the liver. CONCLUSIONS Fibrogenic markers exhibit a differential expression pattern in HCC versus non-tumorous tissue in explanted livers of patients undergoing LT, showing a correlation with HCC recurrence.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28729525     DOI: 10.12659/aot.903497

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  4 in total

1.  Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma.

Authors:  Diana Julie Leeming; Signe Holm Nielsen; Roslyn Vongsuvanh; Pruthviraj Uchila; Mette Juul Nielsen; Alexander L Reese-Petersen; David van der Poorten; Mohammed Eslam; Detlef Schuppan; Morten Asser Karsdal; Jacob George
Journal:  Hepat Oncol       Date:  2020-12-18

2.  A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma.

Authors:  Yao Liu; Le Sun; Fangyuan Gao; Xue Yang; Yuxin Li; Qun Zhang; Bingbing Zhu; Shuaishuai Niu; Yunyi Huang; Ying Hu; Ying Feng; Yuyong Jiang; Xianbo Wang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

3.  Promyelocytic leukemia protein deficiency leads to spontaneous formation of liver tumors in hepatitis C virus transgenic mice.

Authors:  Katja Straub; Peri Husen; Hideo A Baba; Martin Trippler; Heiner Wedemeyer; Kerstin Herzer
Journal:  Cancer Med       Date:  2019-05-29       Impact factor: 4.452

4.  Long-term outcome of intraoperative radiofrequency ablation for hepatocellular carcinoma and its efficacy as a primary treatment.

Authors:  Jongduk Kwon; Kwang-Sik Chun; In-Sang Song; Seok-Hwan Kim; Sunjong Han
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2020-02-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.